MS Society to relaunch clinical trials network

MS Society to launch MS Clinical Trials Network. #MSBlog #MSResearch

“The MS Society is relaunching their clinical trials network (CTN) today at a meeting in London. The CTN is an initiative to stimulate and help researchers in the UK to do investigator-led clinical studies in MS. The following is the programme and I have put together a short survey to allow you to ask questions. I can’t promise if I will be able to answer them all.”

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.


  • I'm really looking forward to your report on this event. Dr. Coles giving us more data on alemtuzumab; the trial proposal of IV (I presume) cladribine v alemtuzumab. So much interesting stuff. I don't suppose it's going to be on youtube?

  • I can't give you a report as it is not for me to talk about his unpublished data. He did present his data set of twelve year and the conversion to spms. All i will say is that doctor coles believe that the best efficacy will be seen if used earlier rather than later

    Doctor Klaus presented a study that could be subcutaneous or iv 70k vs 2k

    • We know that people can progress after alemtuzumab look at the published data there question is how early is early

    • Prof Mouse, unfortunately I found nothing on this aside from "may be if we treat very early, …", but no any clue on conversion rate in treated MSers. May be I tried not so hard, but looks like there is no accessible data. (the good thing is that I found this wonderful blog while searched on this topic). Thanks anyway.

    • The cracks are already appearing. I saw my neurologist today and she isn't convinced that alemtuzamab will be effective after a second relapse. The big question is how soon is soon enough? She reiterated the concept that relapses and progression are entirely exclusive. She showed me data she's compiled illustrating this. She also spoke of the massive risks of alemtuzamab, though she did state that most of her patients are tolerating the drug well.

      I have to say that not everybody in neurology is as smitten as what this blog is when it comes to alemtuzamab.

    • What do you mean by effective? It is effective in the majority of cases in stopping relapses and inflammation; does is stop progression from RRMS to SPMS, that's the thousand dollar question. My son had it within 3 years of being diagnosed, but he'd had a number of relapses, even when on rebif. Since then he's had no relapses and a stable MRI

    • No Relapses and a stable MRI sounds good to me.

      Does it stop?….the problem is what is the comparison whilst trials are ongoing you have good data but after it becomes more woolley and so do you compare to historical data or not. i know you want answers but it is not my data to dissect or tell.

    • Anon 06:39pm,

      I was wondering if you would be in a position to say if your son had fatigue before his treatment and if it improved afterwards?

      I know Tysabri oftent helps in this way, information on alemtuzumab seems sketchy.


    • I don't know. When he was having his relapses he got tired walking to the pub ( I know some MSers would love to be able to do that, but it was early disease) and couldn't stand for too long, and ended up kicking himself when he tried to swim. Now he's back to playing 5 a side football

  • Furthermore i did not say how many converted remember it could be zero. Once a journal accepts the publication i am sure dr coles will reveal all.

  • The cracks are already appearing.

    Some MSers are Risk Averse, Some Neuros are Risk Averse, Some Neuros do not accept that sufficient efficacy has been shown. Some Neuros believe that relapses and progression are exclusive some believe they are linked. Some Neuros believe that inflammation is a good thing, Some people think the Earth is flat.

    Neuro is not convinced that Alemtuzumab is effective after two relapses. Read ProfG post on how many people need more than the the two courses of alemtuzumab and if you look at entry criteria for trials how many had less two relapses as the entry criteria at least one of trials was at least two attacks during previous two years. However, this is data we want to know i.e. chance of NEDA after each attack, but you could have two lesions and they go unnoticed or two lesions and devastation.

By Prof G



Recent Posts

Recent Comments